Bulletin
Investor Alert

Biogen Inc.

NAS: BIIB

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 21, 2022, 7:50 p.m.

/zigman2/quotes/201531540/composite

$

221.04

Change

+0.52 +0.24%

Volume

Volume 537,349

Quotes are delayed by 20 min

/zigman2/quotes/201531540/composite

Previous close

$ 225.91

$ 220.52

Change

-5.39 -2.39%

Day low

Day high

$220.29

$226.37

Open

52 week low

52 week high

$217.10

$468.55

Open

Company Description

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment o...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Valuation

P/E Current

9.31

P/E Ratio (with extraordinary items)

22.19

P/E Ratio (without extraordinary items)

9.87

Price to Sales Ratio

3.20

Price to Book Ratio

3.49

Price to Cash Flow Ratio

9.34

Enterprise Value to EBITDA

9.21

Enterprise Value to Sales

4.51

Total Debt to Enterprise Value

0.18

Efficiency

Revenue/Employee

1,357,802.00

Income Per Employee

439,626.00

Receivables Turnover

5.15

Total Asset Turnover

0.48

Liquidity

Current Ratio

1.84

Quick Ratio

1.55

Cash Ratio

0.70

Profitability

Gross Margin

81.69

Operating Margin

30.76

Pretax Margin

40.85

Net Margin

32.38

Return on Assets

15.43

Return on Equity

33.28

Return on Total Capital

19.80

Return on Invested Capital

21.78

Capital Structure

Total Debt to Total Equity

73.94

Total Debt to Total Capital

42.51

Total Debt to Total Assets

32.14

Long-Term Debt to Equity

73.16

Long-Term Debt to Total Capital

42.06

Officers and Executives

Name Age Officer Since Title
Mr. Michel Vounatsos 58 2016 Chief Commercial Officer & Executive VP
Dr. Alphonse Galdes - 1995 EVP-Pharmaceutical Operations & Technology
Mr. Michael R. McDonnell 55 2020 Chief Financial Officer & Executive Vice President
Dr. Mahalakshmi Radhakrishnan - 2020 Chief Medical Officer & Group Senior VP
Dr. Alfred W. Sandrock 61 1998 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/03/2021 Robin C. Kramer
Chief Accounting Officer
22   Derivative/Non-derivative trans. at $223.92 per share. 4,926
12/03/2021 Robin C. Kramer
Chief Accounting Officer
78   Derivative/Non-derivative trans. at $223.92 per share. 17,465
12/03/2021 Robin C. Kramer
Chief Accounting Officer
265   Derivative/Non-derivative trans. at $223.92 per share. 59,338
12/03/2021 Robin C. Kramer
Chief Accounting Officer
74   Derivative/Non-derivative trans. at $223.92 per share. 16,570
12/02/2021 Rachid Izzar
Head of Alzheimer s Disease
165   Derivative/Non-derivative trans. at $228.52 per share. 37,705
12/02/2021 Rachid Izzar
Head of Alzheimer s Disease
372   Derivative/Non-derivative trans. at $228.52 per share. 85,009
09/01/2021 Michael R. McDonnell
EVP, Chief Financial Officer
1,441   Derivative/Non-derivative trans. at $338.24 per share. 487,403
09/01/2021 Michael R. McDonnell
EVP, Chief Financial Officer
1,141   Derivative/Non-derivative trans. at $338.24 per share. 385,931
09/01/2021 Michael R. McDonnell
EVP, Chief Financial Officer
3,324   Derivative/Non-derivative trans. at $338.24 per share. 1,124,309
09/01/2021 Michael R. McDonnell
EVP, Chief Financial Officer
2,681   Derivative/Non-derivative trans. at $338.24 per share. 906,821
07/01/2021 Stelios Papadopoulos
Director
1,275   Award at $0 per share. 0
07/01/2021 Caroline D. Dorsa
Director
775   Award at $0 per share. 0
07/01/2021 Eric K. Rowinsky
Director
775   Award at $0 per share. 0
07/01/2021 Stephen A. Sherwin
Director
775   Award at $0 per share. 0
07/01/2021 Nancy L. Leaming
Director
775   Award at $0 per share. 0
07/01/2021 Alexander John Denner
Director
775   Award at $0 per share. 0
07/01/2021 Richard Charles Mulligan
Director
775   Award at $0 per share. 0
07/01/2021 Brian S. Posner
Director
775   Award at $0 per share. 0
07/01/2021 Jesus B. Mantas
Director
775   Award at $0 per share. 0
07/01/2021 William A. Hawkins
Director
775   Award at $0 per share. 0
07/01/2021 William D. Jones
Director
775   Award at $0 per share. 0
07/01/2021 Maria C. Freire
Director
775   Award at $0 per share. 0
07/01/2021 Robin C. Kramer
Chief Accounting Officer
251   Derivative/Non-derivative trans. at $348.92 per share. 87,578
07/01/2021 Robin C. Kramer
Chief Accounting Officer
74   Derivative/Non-derivative trans. at $348.92 per share. 25,820
06/07/2021 Alfred W. Sandrock
Head of Research & Development
7,672   Disposition at $440 per share. 3,375,680
06/07/2021 Chirfi Guindo
Head of Glob Prod Strat & Com
3,087   Disposition at $440 per share. 1,358,280
06/04/2021 Brian S. Posner
Director
360   Disposition at $274.17 per share. 98,701
02/12/2021 Michel Vounatsos
Chief Executive Officer; Director
2,367   Derivative/Non-derivative trans. at $278.03 per share. 658,097
02/12/2021 Michel Vounatsos
Chief Executive Officer; Director
2,333   Derivative/Non-derivative trans. at $278.03 per share. 648,643
02/12/2021 Michel Vounatsos
Chief Executive Officer; Director
2,525   Derivative/Non-derivative trans. at $278.03 per share. 702,025
02/12/2021 Michel Vounatsos
Chief Executive Officer; Director
7,248   Derivative/Non-derivative trans. at $278.03 per share. 2,015,161
02/12/2021 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
607   Derivative/Non-derivative trans. at $278.03 per share. 168,764
02/12/2021 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
622   Derivative/Non-derivative trans. at $278.03 per share. 172,934
02/12/2021 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
704   Derivative/Non-derivative trans. at $278.03 per share. 195,733
02/12/2021 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
1,963   Derivative/Non-derivative trans. at $278.03 per share. 545,772
02/12/2021 Alfred W. Sandrock
Head of Research & Development
758   Derivative/Non-derivative trans. at $278.03 per share. 210,746
02/12/2021 Alfred W. Sandrock
Head of Research & Development
642   Derivative/Non-derivative trans. at $278.03 per share. 178,495
02/12/2021 Alfred W. Sandrock
Head of Research & Development
577   Derivative/Non-derivative trans. at $278.03 per share. 160,423
02/12/2021 Alfred W. Sandrock
Head of Research & Development
1,533   Derivative/Non-derivative trans. at $278.03 per share. 426,219
02/12/2021 Ginger Gregory
EVP, Human Resources
474   Derivative/Non-derivative trans. at $278.03 per share. 131,786
02/12/2021 Ginger Gregory
EVP, Human Resources
428   Derivative/Non-derivative trans. at $278.03 per share. 118,996
02/12/2021 Ginger Gregory
EVP, Human Resources
396   Derivative/Non-derivative trans. at $278.03 per share. 110,099
02/12/2021 Ginger Gregory
EVP, Human Resources
884   Derivative/Non-derivative trans. at $278.03 per share. 245,778
02/12/2021 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
282   Derivative/Non-derivative trans. at $278.03 per share. 78,404
02/12/2021 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
96   Derivative/Non-derivative trans. at $278.03 per share. 26,690
02/12/2021 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
84   Derivative/Non-derivative trans. at $278.03 per share. 23,354
02/12/2021 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
253   Derivative/Non-derivative trans. at $278.03 per share. 70,341
02/12/2021 Chirfi Guindo
Head of Glob Prod Strat & Com
477   Derivative/Non-derivative trans. at $278.03 per share. 132,620
02/12/2021 Chirfi Guindo
Head of Glob Prod Strat & Com
463   Derivative/Non-derivative trans. at $278.03 per share. 128,727
02/12/2021 Robin C. Kramer
Chief Accounting Officer
73   Derivative/Non-derivative trans. at $278.03 per share. 20,296
02/12/2021 Robin C. Kramer
Chief Accounting Officer
42   Derivative/Non-derivative trans. at $278.03 per share. 11,677
02/12/2021 Michel Vounatsos
Chief Executive Officer; Director
5,337   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Michel Vounatsos
Chief Executive Officer; Director
5,259   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Michel Vounatsos
Chief Executive Officer; Director
5,693   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
1,367   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
1,402   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
1,586   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Alfred W. Sandrock
Head of Research & Development
1,708   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Alfred W. Sandrock
Head of Research & Development
1,446   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Alfred W. Sandrock
Head of Research & Development
1,300   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Ginger Gregory
EVP, Human Resources
1,068   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Ginger Gregory
EVP, Human Resources
964   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Ginger Gregory
EVP, Human Resources
891   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
960   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
327   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
286   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Chirfi Guindo
Head of Glob Prod Strat & Com
1,622   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Chirfi Guindo
Head of Glob Prod Strat & Com
1,534   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Robin C. Kramer
Chief Accounting Officer
213   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Robin C. Kramer
Chief Accounting Officer
120   Derivative/Non-derivative trans. at $0 per share. 0
02/09/2021 Jesus B. Mantas
Director
898   Acquisition at $267 per share. 239,766
01/27/2021 Michel Vounatsos
Chief Executive Officer; Director
16,343   Award at $0 per share. 0
01/27/2021 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
4,545   Award at $0 per share. 0
01/27/2021 Alfred W. Sandrock
Head of Research & Development
3,728   Award at $0 per share. 0
01/27/2021 Ginger Gregory
EVP, Human Resources
2,558   Award at $0 per share. 0
01/27/2021 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
818   Award at $0 per share. 0
12/31/2020 Robert W. Pangia
Director
16,000   Gift at $0 per share. 0
12/31/2020 Robert W. Pangia
Director
16,000   Gift at $0 per share. 0
/news/latest/company/us/biib

MarketWatch News on BIIB

  1. Why Biogen Could Need to Sell 'for Parts'

    9:41 a.m. Jan. 18, 2022

    - Josh Nathan-Kazis

  2. Biogen stock price target cut to $202 vs. $290 at Guggenheim

    7:16 a.m. Jan. 13, 2022

    - Ciara Linnane

  3. Biogen downgraded to neutral vs. buy at Guggenheim

    7:16 a.m. Jan. 13, 2022

    - Ciara Linnane

  4. Medicare pulls back on coverage of an Alzheimer’s drug

    10:13 a.m. Jan. 12, 2022

    - Paul Brandus

  5. Biogen Trips Again on Alzheimer's Drug

    8:11 a.m. Jan. 12, 2022

    - Jacob Sonenshine

  6. Biogen stock tumbles 9.5% toward 2 1/2-yr. low premarket after CMS to limit coverage for Alzheimer’s drug

    6:04 a.m. Jan. 12, 2022

    - Tomi Kilgore

  7. Biogen stock price target cut to $207 from $270 at Mizuho

    6:00 a.m. Jan. 12, 2022

    - Tomi Kilgore

  8. Biogen’s Alzheimer’s Drug Has Another Shot at Success

    1:18 p.m. Jan. 8, 2022

    - Josh Nathan-Kazis

  9. Biogen’s Alzheimer’s Drug Has Another Shot at Success

    3:46 p.m. Jan. 7, 2022

    - Josh Nathan-Kazis

  10. Loading more headlines...
/news/nonmarketwatch/company/us/biib

Other News on BIIB

  1. Is Biogen a Buy?

    10:00 a.m. Today

    - Motley Fool

  2. 3 Clinical Trials to Watch in the First Half of 2022

    8:46 a.m. Today

    - Motley Fool

  3. Alzheimer's groups protest CMS decision on Biogen's Aduhelm

    11:12 a.m. Jan. 21, 2022

    - Seeking Alpha

  4. Is Biogen a Buy After the Latest Aduhelm Disaster?

    6:40 a.m. Jan. 17, 2022

    - Motley Fool

  5. Where Will Biogen Be in 5 Years?

    6:36 a.m. Jan. 15, 2022

    - Motley Fool

  6. Biogen Is More Likely to Be a Buyer Than Seller

    2:56 p.m. Jan. 14, 2022

    - GuruFocus.com

  7. 4 Biotech Acquisitions We'd Like to See in 2022

    6:10 a.m. Jan. 14, 2022

    - Motley Fool

  8. Longleaf Partners Comments on Biogen

    3:32 p.m. Jan. 13, 2022

    - GuruFocus.com

  9. Longleaf Partners Fund's 4th-Quarter Commentary

    3:13 p.m. Jan. 13, 2022

    - GuruFocus.com

  10. Stocks Edge Higher as Inflation Picks Up

    4:48 p.m. Jan. 12, 2022

    - Karen Langley

  11. Aduhelm And Medicare

    3:38 p.m. Jan. 12, 2022

    - Seeking Alpha

  12. Loading more headlines...

At a Glance

Biogen, Inc.

225 Binney Street

Cambridge, Massachusetts 02142

Phone

1 6176792000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$12.36B

Net Income

$4.00B

Employees

9,100

/news/pressrelease/company/us/biib

Press Releases on BIIB

  1. Biogen Inc. Common Stock BIIB Technical Analysis

    5:41 p.m. Jan. 13, 2022

    - Stock Traders Daily

  2. Nasdaq 100 Movers: BIIB, OKTA

    10:38 a.m. Jan. 12, 2022

    - MarketNewsVideo.com

  3. S&P 500 Movers: BIIB, TTWO

    10:37 a.m. Jan. 12, 2022

    - MarketNewsVideo.com

  4. Biogen's Controversial Alzheimer Drug

    9:57 a.m. Jan. 5, 2022

    - Baystreet.ca

  5. Biogen Inc. Common Stock BIIB Investment Analysis

    11:33 p.m. Jan. 3, 2022

    - Stock Traders Daily

  6. Nasdaq 100 Movers: CDNS, LCID

    10:45 a.m. Dec. 31, 2021

    - MarketNewsVideo.com

  7. Nasdaq 100 Movers: BIIB, PTON

    10:23 a.m. Dec. 30, 2021

    - MarketNewsVideo.com

  8. S&P 500 Movers: BIIB, VIAC

    10:22 a.m. Dec. 30, 2021

    - MarketNewsVideo.com

  9. Biogen Inc. Common Stock BIIB Trading Report

    4:07 a.m. Dec. 25, 2021

    - Stock Traders Daily

  10. Loading more headlines...
Link to MarketWatch's Slice.